Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | CKS1B | P61024 | 5/20 | 0.40 |
| ▸ | SKP1 | P63208 | 5/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 5/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244732 | 0.84 | HDAC6 (0.57) | HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL13304573 | 0.74 | HDAC6 (0.52) | HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL13304558 | 0.66 | HDAC6 (0.60) | HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL13304564 | 0.65 | HDAC6 (0.54) | HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL13304478 | 0.65 | HDAC6 (0.56) | HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL13304603 | 0.64 | HDAC6 (0.53) | HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL27402514 | 0.64 | SLC6A2 (0.44) | — | |
| SCHEMBL31662528 | 0.64 | DRD2 (0.50) | HDAC1 | |
| SCHEMBL1728812 | 0.63 | CKS1B (0.56) | CKS1BSKP1SKP2 | |
| SCHEMBL19759609 | 0.62 | ROCK2 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160321-A1 | IMIDAZOLINONE AND HYDANTOINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160321-A1 | IMIDAZOLINONE AND HYDANTOINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160321-A1 | IMIDAZOLINONE AND HYDANTOINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.